Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Update

Avenue Therapeutics, Inc. (NASDAQ:ATXI) saw a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 44,100 shares, a decline of 13.4% from the October 31st total of 50,900 shares. Approximately 2.4% of the company’s shares are sold short. Based on an average daily volume of 44,300 shares, the short-interest ratio is presently 1.0 days.

Institutional Trading of Avenue Therapeutics

An institutional investor recently bought a new position in Avenue Therapeutics stock. Armistice Capital LLC purchased a new position in Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned approximately 7.97% of Avenue Therapeutics at the end of the most recent reporting period. 17.34% of the stock is owned by institutional investors.

Avenue Therapeutics Stock Performance

NASDAQ ATXI opened at $1.94 on Tuesday. The stock has a market cap of $3.71 million, a P/E ratio of 0.12 and a beta of -0.17. Avenue Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $26.47. The stock has a 50 day simple moving average of $2.15 and a two-hundred day simple moving average of $2.80.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.